Direct HIV testing in blood donations: variation of the yield with detection threshold and pool size

被引:26
作者
Le Corfec, E
Le Pont, F
Tuckwell, HC
Rouzioux, C
Costagliola, D
机构
[1] Inst Federat Rech Sante St Antoine, INSERM U444, F-75572 Paris 12, France
[2] Hop Necker Enfants Malad, Virol Lab, Paris, France
关键词
D O I
10.1046/j.1537-2995.1999.39101141.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: This study was designed to evaluate the potential yield of introducing nucleic acid amplification testing (NAT) in blood donation, according to the detection threshold and the pool size. STUDY DESIGN AND METHODS: A mathematical model of early HIV-1 population dynamics in blood has been developed and is used to predict the window period for NAT, according to the detection threshold and the pool size. The corresponding number of undetected, infected blood donations and the residual risk are estimated by using a previously published simulation model for the United States (9.96 million blood donations from regular donors, and an observed rate of HIV antibody-positive blood donations of 3.18/100,000) and for France (2.32 million blood donations, and a rate of antibody-positive donations of 0.9/100,000). RESULTS: The average window period from infection predicted by the mathematical model for NAT ranges from 8.4 to 15.6 days, according to the detection threshold and the pool size. The maximum yield of adding NAT to the current antibody tests is estimated at 1 LC donations for the United States and 2 for France. The maximum yield of adding NAT to the newly developed combined HIV antibody and p24 antigen tests is 7 donations for the United States and 1 for France. CONCLUSION: NAT at blood donation could reduce the HIV-1 window period to a minimal value of 8 days without pooling the blood samples, but the yield of NAT would be close to that of combined HIV antibody and p24 antigen tests for high values of the detection threshold and the pool size.
引用
收藏
页码:1141 / 1144
页数:4
相关论文
共 15 条
  • [11] HIGH-LEVELS OF HIV-1 IN PLASMA DURING ALL STAGES OF INFECTION DETERMINED BY COMPETITIVE PCR
    PIATAK, M
    SAAG, MS
    YANG, LC
    CLARK, SJ
    KAPPES, JC
    LUK, KC
    HAHN, BH
    SHAW, GM
    LIFSON, JD
    [J]. SCIENCE, 1993, 259 (5102) : 1749 - 1754
  • [12] The risk of transfusion-transmitted viral infections
    Schreiber, GB
    Busch, MP
    Kleinman, SH
    Korelitz, JJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) : 1685 - 1690
  • [13] Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant
    Sperling, RS
    Shapiro, DE
    Coombs, RW
    Todd, JA
    Herman, SA
    McSherry, GD
    OSullivan, MJ
    VanDyke, RB
    Jimenez, E
    Rouzioux, C
    Flynn, PM
    Sullivan, JL
    Spector, SA
    Diaz, C
    Rooney, J
    Balsley, J
    Gelber, RD
    Connor, EM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (22) : 1621 - 1629
  • [14] A stochastic Model for early HIV-1 population dynamics
    Tuckwell, HC
    Le Corfec, E
    [J]. JOURNAL OF THEORETICAL BIOLOGY, 1998, 195 (04) : 451 - 463
  • [15] TUCKWELL HC, 1995, ELEMENTARY APPL PROB